All In Biotech

Free tool

FAERS Monitor: Onivyde

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 207793 or its brand name (Onivyde, Irinotecan Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

9,837

Serious

9,369

95% of reports

Hospitalization

3,831

Death reported

1,809

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea1,225
  • off label use980
  • myelosuppression719
  • nausea645
  • vomiting569
  • malignant neoplasm progression548
  • febrile neutropenia538
  • death512
  • neutropenia468
  • neuropathy peripheral443
  • disease progression426
  • fatigue420
  • pyrexia383
  • neutrophil count decreased354
  • asthenia343

Reports by year received

View as table
YearReports
200411
20059
20066
20072
2008143
200984
2010123
2011224
2012291
2013243
2014158
2015335
2016312
2017313
2018414
2019488
2020548
2021638
2022863
20231,022
20241,083
20251,475
20261,052

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,322 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
myelosuppressionSignal71943.540.529,290
neutrophil count decreasedSignal35418.716.95,882
febrile neutropeniaSignal53817.516.18,298
malignant neoplasm progressionSignal54811.510.65,239
neuropathy peripheralSignal44310.09.13,579
disease progressionSignal4267.77.02,491
neutropeniaSignal4687.46.82,583
diarrhoeaSignal1,2254.13.92,910
vomitingSignal5692.62.4566
off label useSignal9802.42.3828
pyrexiaSignal3832.42.1306
asthenia3432.01.8161
nausea6451.71.6211
death5121.31.231
fatigue4201.21.19

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.